Meletios Dimopoulos, MD, of the University of Athens School of Medicine, Athens, Greece, gives an overview of the OPTIMISMM trial…
Browsing: Multiple Myeloma
In this interview, recorded at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Meletios Dimopoulos, MD,…
BCMA is an exciting therapeutic target for multiple myeloma (MM). Here, Yi Lin, MD, PhD, of the Mayo Clinic, Rochester,…
Multiple myeloma (MM) is at the forefront of immunotherapeutic developments, including T-cell therapies and bispecific antibodies. Here, our expert panel…
Understanding the mechanisms of drug resistance in multiple myeloma (MM) is vital in order to improve treatment. In this comprehensive…
Ivan Borrello, MD, of Johns Hopkins University School of Medicine, Baltimore, MD, discusses the role of the microenvironment in multiple…
Is measurable residual disease (MRD) ready for prime time in multiple myeloma (MM)? Gareth Morgan, MD, PhD, FRCP, FRCPath, of…
Keith Stewart, MB, ChB, of the Mayo Clinic, Rochester, MN, rounds up the Myeloma 2018 meeting, held in San Diego,…
The experts at the Myeloma 2018 meeting in San Diego, CA, discussed the successes, challenges and future outlook for CAR…
From the Myeloma 2018 meeting, held in San Diego, CA, the experts discuss novel targets in multiple myeloma (MM), including…
The progression to multiple myeloma (MM) in patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)…
In this exciting discussion, the experts explore the prevocative question of ‘is precision medicine a bust in multiple myeloma?’ Topics…
From the Myeloma 2018 meeting, held in San Diego, CA, Gareth Morgan, MD, PhD, FRCP, FRCPath, of UAMS Myeloma Institute,…
Keith Stewart, MB, ChB from the Mayo Clinic, Rochester, MN, is joined by Kenneth Anderson, MD, of the Dana-Farber Cancer…
CAR T-cells are an exciting new therapeutic area in multiple myeloma (MM). Here, the experts discuss the current landscape of…
CRISPR technology is being used to define mechanisms of multiple myeloma (MM) drug resistance. Here, Constantine Mitsiades, MD, PhD, of…
John P. Fruehauf, MD, UC Irvine Health, Looks at Data from Combination Studies | ASCO 2019 Will Show The Role…
John P. Fruehauf, MD, UC Irvine Health, explains New Treatment for Melanoma is Working Everywhere | Working For Metastatic Disease…
John P. Fruehauf, MD, UC Irvine Health, Looks at Combinations of Therapies | Combine Targeted BRAF Agents with Immunotherapy at…
John P. Fruehauf, MD, UC Irvine Health, explains Practice-Changing Impact of Presented Data | Durability to the Benefit of Immunotherapy…
John P. Fruehauf, MD, UC Irvine Health, explains What to do with Stage 3 Disease | Which is a Better…
John P. Fruehauf, MD, UC Irvine Health, explains how 50% of Melanoma Patients Develop Brain Metastases | BRAF-MEK & Immunotherapy…
John P. Fruehauf, MD, UC Irvine Health, explains New Agents for BRAF-MEK Inhibition | Binimetinib/Encorafenib at MOASC 2018
John P. Fruehauf, MD, UC Irvine Health, explains KEYTRUDA & Role in Stage 4 Melanoma | Immunotherapy has Long-Term Benefits…
Nikhil Munshi, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses exciting novel avenues for multiple myeloma (MM) therapy from…
Philip McCarthy, MD, of Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses new strategies for clinical trial design in multiple…
Nikhil Munshi, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses considerations in the treatment of high risk multiple myeloma…
Philip McCarthy, MD, of Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses two Phase III multiple myeloma (MM) transplantation studies…
Monika Engelhardt, MD, of the University Medical Center Freiburg, Freiburg, Germany, speaking from the 1st European Myeloma Network (EMN) Meeting…
Nikhil Munshi, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses advances in the classification of high risk multiple myeloma…
Speaking from the 23rd congress of the European Hematology Association (EHA) 2018 press briefing, held in Stockholm, Sweden, Dr Jesús…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Rafael Fonseca, MD, of the…
In this interview, Rafael Fonseca, MD, of the Mayo Clinic, Phoenix, AZ, discusses how measurable residual disease (MRD) should be…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Rafael Fonseca, MD, of the…
The treatment of multiple myeloma (MM) can be very costly. Speaking from the American Society of Oncology (ASCO) 2018 Annual…
Rafael Fonseca, MD, of the Mayo Clinic, Phoenix, AZ, discusses the situations in which measurable residual disease (MRD) should and…
John P. Fruehauf, MD, UC Irvine Health, Axillary Dissection in Stage 2 or 3 Melanoma | No Benefit from Taking…
Nicola Giuliani, MD, PhD, from the University of Parma, Parma, Italy, talks about the clinical approach required when identifying and…
Speaking at the 1st European Myeloma Network (EMN) Meeting, held in Turin, Italy, Nicola Giuliani, MD, PhD, from the University…
Paul Richardson, MD, from Dana-Farber Cancer Institute, Boston, MA, discusses the exciting results of the Phase III OPTIMISMM trial (NCT01734928)…
The CRB-401 trial (NCT02658929) aims to investigate the efficacy of bb2121 for multiple myeloma (MM) patients. In this interview, recorded…
Measurable residual disease (MRD) analysis is becoming increasingly commonplace as a prognostic indicator and tool for guiding the management of…
Nikhil Munshi, MD, of the Dana-Farber Cancer Institute, Boston, MA, presented results from the CRB-401 trial (NCT02658929) at the 23rd…
Lenalidomide is widely used for multiple myeloma (MM); however, while it is effective, most patients relapse and become lenalidomide-refractory. In…
Understanding the mutations and whole-genome interactions taking place in multiple myeloma (MM) is crucial for disease understanding and therapy research.…
Shaji Kumar, MD, of the Mayo Clinic, Rochester, MN, presents the results of some preclinical and clinical trials investigating the…
Speaking from the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, Paul Richardson, MD, of…
The response of patients with multiple myeloma (MM) to therapy is always variable. Speaking from the 23rd Congress of the…
Defibrotide has previously been studied in post-stem cell transplant patients with veno-occlusive disease with a suitable investigational new drug (IND).…
Many tumor cells are able to evade apoptosis, with the potential to survive in the body indefinitely. Here, Shaji Kumar,…